Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

Full text
Author(s):
Margatho, Deborah [1] ; Carvalho, Nelsilene Mota [1] ; Eloy, Larissa [2] ; Bahamondes, Luis [1]
Total Authors: 4
Affiliation:
[1] Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Dept Pathol, Med Sch, Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 23, n. 5, p. 344-350, 2018.
Web of Science Citations: 0
Abstract

Objective: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS): cancer antigen (CA)-125, cluster of differentiation (CD) 23 and endometrial nerve fibre density. Methods: The study was conducted at the Department of Obstetrics and Gynaecology, University of Campinas Medical School, Brazil. A total of 103 women with endometriosis-associated pain diagnosed by surgery, transvaginal ultrasound and/or magnetic resonance imaging were included. Endometrial nerve fibre density and serum levels of CA-125 and soluble CD23 were assessed before and after six months of using the allocated method and were correlated to 10 cm visual analogue scale (VAS) scores for non-cyclical pelvic pain and dysmenorrhoea. Results: Both contraceptive methods significantly reduced concentrations of serum soluble CD23 and endometrial nerve fibre density (p < .001); however, CA-125 was significantly reduced only among users of the ENG implant (p < .05). No correlation was observed between reduction of biomarkers and improvement of VAS pain and dysmenorrhoea scores. No differences were observed between the ENG implant and the LNG-IUS. Conclusion: Both progestin-only contraceptives significantly reduced two out of the three biomarkers evaluated. These two biomarkers could, therefore, be used as surrogate markers to follow up medical treatment of endometriosis-associated pain. (AU)

FAPESP's process: 15/20504-9 - Clinical findings among progestin-only contraceptives' users
Grantee:Luis Guillermo Bahamondes
Support Opportunities: Research Projects - Thematic Grants